Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 4/20 | 0.50 |
| ▸ | CCNH | P51946 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | BCR | P11274 | 2/20 | 0.47 |
| ▸ | ABL2 | P42684 | 1/20 | 0.47 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.43 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.43 |
| ▸ | PIKFYVE | Q9Y2I7 | 3/20 | 0.42 |
| ▸ | CDK8 | P49336 | 7/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18346365 | 0.89 | CDK7 (0.55) | CDK7CCNHPIP4K2APIP4K2BPIKFYVE | |
| SCHEMBL20228983 | 0.85 | MAP3K5 (0.42) | CDK7CCNHABL1BCRCDK8 | |
| SCHEMBL20225382 | 0.84 | CDK7 (0.75) | CDK7CCNHPIP4K2APIP4K2BCCNT1 | |
| SCHEMBL18346280 | 0.79 | ABL1 (0.41) | ABL1BCRABL2PIKFYVEPDGFRB | |
| SCHEMBL20225394 | 0.78 | CDK7 (0.46) | CDK7CCNHPIP4K2APIP4K2BCDK8 | |
| SCHEMBL18346366 | 0.74 | EGFR (0.55) | CDK7CCNHPIP4K2APIP4K2BCDK8 | |
| SCHEMBL20211532 | 0.73 | CDK7 (0.63) | CDK7CCNHPIP4K2APIP4K2BCCNT1 | |
| SCHEMBL20211533 | 0.73 | CDK7 (0.63) | CDK7CCNHPIP4K2APIP4K2BCCNT1 | |
| SCHEMBL18346372 | 0.73 | CDK7 (0.53) | CDK7CCNHPIP4K2APIP4K2BCCNT1 | |
| SCHEMBL20225392 | 0.73 | CDK7 (0.52) | CDK7CCNHABL1BCRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180369243-A9 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3313529-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210291-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369243-A9 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | CDK7 5/4885CCNH 65/4885ABL1 590/4885 |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | CDK3, CDK14, CDK1 | CDK7 5/4885CCNH 65/4885ABL1 590/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | CDK7 5/4885CCNH 65/4885ABL1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.